Top Page
Jacobio Pharmaceuticals Group Co., Ltd.
(1167)
Jacobio Pharmaceuticals Group Co., Ltd. (1167) vs. iShares MSCI Hong Kong ETF (EWH)
Jacobio Pharmaceuticals Group Co., Ltd. Business Overview & Revenue Model
Jacobio Pharmaceuticals Group Co., Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 201.37M | 155.71M | 63.52M | 95.75M | 152.81M | 486.29M |
| Gross Profit | 201.37M | 155.71M | 3.20M | 12.63M | 12.83M | 442.17M |
| EBITDA | -72.93M | -192.36M | -325.73M | -355.80M | -289.83M | -1.50B |
| Net Income | -45.65M | -155.71M | -359.12M | -371.86M | -301.19M | -1.51B |
Balance Sheet | ||||||
| Total Assets | 1.29B | 1.36B | 1.46B | 1.57B | 1.72B | 1.87B |
| Cash, Cash Equivalents and Short-Term Investments | 1.07B | 1.17B | 1.15B | 1.28B | 1.54B | 1.63B |
| Total Debt | 143.01M | 152.08M | 209.91M | 147.79M | 6.81M | 10.65M |
| Total Liabilities | 423.87M | 435.99M | 387.11M | 292.12M | 84.75M | 81.15M |
| Stockholders Equity | 867.38M | 923.18M | 1.07B | 1.28B | 1.64B | 1.79B |
Cash Flow | ||||||
| Free Cash Flow | 99.69M | -86.21M | -402.86M | -308.92M | -158.63M | 67.87M |
| Operating Cash Flow | 106.31M | -74.12M | -364.20M | -292.42M | -147.49M | 78.83M |
| Investing Cash Flow | 212.53M | 256.22M | -48.00M | -686.32M | 161.67M | -215.56M |
| Financing Cash Flow | -4.48M | 21.28M | 246.28M | -9.85M | 109.06M | 1.28B |
Jacobio Pharmaceuticals Group Co., Ltd. Technical Analysis
Jacobio Pharmaceuticals Group Co., Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | HK$1.54B | 189.52 | 0.99% | ― | 9.41% | -32.69% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | HK$5.09B | 27.61 | 4.45% | ― | -8.11% | ― | |
| ― | HK$9.18B | -20.28 | -95.84% | ― | -55.64% | -158.67% | |
| ― | HK$3.34B | ― | -129.05% | ― | ― | -18.99% | |
| ― | HK$2.24B | ― | -55.33% | ― | -100.00% | 30.68% | |
| ― | HK$5.82B | ― | -5.08% | ― | 770.20% | 87.27% |
Jacobio Pharmaceuticals Group Co., Ltd. Corporate Events
Jacobio Pharmaceuticals announced the presentation of preclinical data for their pan-KRAS inhibitor, JAB-23E73, at the AACR-NCI-EORTC 2025 conference. The data indicates that JAB-23E73 shows strong antitumor activity and good tolerability in KRAS-driven cancer models, with ongoing Phase I trials in China and the U.S. This advancement could enhance Jacobio’s position in the oncology sector, potentially impacting stakeholders positively if successful.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
Jacobio Pharmaceuticals Group Co., Ltd. has announced a capital increase and equity transfer agreement involving its subsidiaries and partners, including Oceanpine Capital. This strategic move allows Jacobio to focus on its core oncology therapies while optimizing capital allocation and enhancing organizational efficiency. The proceeds from the transaction will be used to advance the company’s Pan-KRAS inhibitor and other innovative oncology projects, aligning with its strategic goals and benefiting shareholders.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$5.30 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
Jacobio Pharmaceuticals Group Co., Ltd. has announced changes in shareholdings among its Concert Parties, with a significant purchase of 11,058,650 shares, reflecting strong confidence in the company’s growth potential and long-term investment value. Additionally, the company has been actively repurchasing its shares on the market, with a total of 326,400 shares bought back, as part of a larger HK$100 million share repurchase plan, indicating the board’s belief that the current share price undervalues the company’s intrinsic worth.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$5.30 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
Jacobio Pharmaceuticals Group Co., Ltd. announced that parties acting in concert with the company have increased their shareholdings by purchasing 402,000 shares on the open market. This move reflects strong confidence in the company’s development prospects and growth potential, with the concert parties now holding approximately 25.41% of the total issued shares. The increase in shareholding is in line with applicable laws and regulations, and further increases are not ruled out.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$5.30 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
Jacobio Pharmaceuticals announced its interim results for the first half of 2025, highlighting significant progress in its drug pipeline. Key achievements include the market approval of glecirasib for NSCLC patients with KRAS G12C mutations, and promising results from trials involving sitneprotafib and other investigational drugs. The company is advancing its clinical trials in China and the U.S., with ongoing studies in multiple cancer types, including a pivotal Phase II basket study. These developments underscore Jacobio’s commitment to expanding its oncology portfolio and enhancing its market position.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$5.30 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
Jacobio Pharmaceuticals Group Co., Ltd. has outlined the terms of reference for its Nomination Committee, which was established to review and recommend board appointments and ensure compliance with applicable laws and regulations. The committee will consist mainly of independent non-executive directors, and it will meet at least once annually to fulfill its duties, impacting the company’s governance structure and potentially its strategic direction.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$5.30 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
Jacobio Pharmaceuticals Group Co., Ltd. has announced a board meeting scheduled for August 29, 2025, to consider and approve the interim results for the first half of the year. This meeting is significant as it will address the company’s financial performance and potentially influence its strategic direction and stakeholder interests.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$3.70 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
Jacobio Pharmaceuticals Group Co., Ltd. announced that its parties acting in concert have increased their shareholdings by purchasing an additional 60,900 shares on the open market. This move reflects strong confidence in the company’s growth prospects and long-term investment value, with the Concert Parties now holding approximately 25.36% of the total issued shares. The shareholding increase was conducted in compliance with applicable laws and regulations, and there is potential for further increases in the future.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$3.70 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.